MyOme offers a comprehensive genetic testing service through its MyOme Personal Genome™ platform, which utilizes clinical-grade whole genome sequencing to provide extensive health insights. This technology analyzes over 3 billion bases of DNA, delivering a more complete picture of an individual's disease risk compared to traditional genetic tests that typically focus on a limited number of genes. The platform generates two initial reports: a Proactive Health Report and a Pharmacogenomics Report, which assess risks for various conditions and medication responses. MyOme's approach is designed to evolve with advancements in genetic research, allowing for ongoing updates to health insights as new findings emerge.

In addition to its robust testing capabilities, MyOme emphasizes the importance of personalized healthcare through genetic counseling and independent physician reviews. The platform is committed to data privacy, ensuring that users have control over their genetic information and that it is protected under HIPAA compliance. MyOme also plans to introduce integrated personal risk score reports that combine genetic data with clinical factors, enhancing the ability to assess health risks across diverse ancestries. This dynamic and patient-centered approach positions MyOme as a leader in the field of personalized genomics, enabling individuals to make informed health decisions throughout their lives.

United States

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

MyOme

Company Details